INS and fatty liver disease: Rapamycin, a well-known mTORC1 inhibitor, has been shown to decrease liver fat accumulation, lower serum alanine aminotransferase (ALT) levels, and improve insulin sensitivity in mouse models of fatty liver disease [169,170].